Skip to contentS
Sanara MedTech Inc.
S
SMTISanara MedTech Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$27.55M$27.55Mderived+4.7% vs Q4 2024 Net Income-$1.61M-$1.61MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sanara MedTech Inc. · CIK 714256 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$25,671,309+6.7% Operating Incomederived$1,050,459−78.5% Operating Cash Flowderived$3,945,061+323.3% Free Cash Flowderived$3,862,902+349.2% Margins · derivedGross margin93.2%+1.7 pt vs Q4 2024
Operating margin3.8%−14.8 pt vs Q4 2024
Net margin-5.8%+0.0 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 24, 2026 · 83 d after period end